Target intelligence / Profile preview

β-1,3-D-glucan synthase enzyme complex (Fks1 complex)

Target
Fks1 complex
Molecular classification
Enzyme, Membrane protein complex, Glycosyltransferase (GT48 family for main catalytic subunit in fungi), Multisubunit complex
01

Overview

The **β-1,3-D-glucan synthase enzyme complex** is an essential membrane-bound enzyme assembly found in fungi, catalyzing the polymerization of glucose into linear β-1,3-glucan, the major structural component of the fungal cell wall[3][4][6]. The complex includes a catalytic subunit (commonly Fks1 in yeast/fungi), as well as a small GTPase regulatory subunit (Rho1), anchored to the membrane and essential for activity[3][4]. Its activity is absent in mammalian and bacterial cells, making it an ideal, highly selective target for antifungal therapies[4][7]. Drugs targeting this complex (notably echinocandins and ibrexafungerp) inhibit β-glucan biosynthesis, compromising fungal cell wall strength and ultimately causing cell death[4][7]. Resistance to these drugs arises mainly through mutations in the *FKS* genes encoding the catalytic subunits[4]. Detection of β-D-glucan in body fluids is also used as a surrogate marker for invasive fungal infections due to the importance of β-1,3-D-glucan in pathogenic fungi[6].

Other names
β-1,3-glucan synthaseGSFks1 complex (refers to primary catalytic subunit in many fungi)FK506-supersensitive protein 1 (FKS1, gene for the major subunit in yeast)FKS2, FKS3 (alternative fungal isoforms)Beta-glucan synthase1,3-beta-D-glucan synthaseβ-D-glucan synthase complex
02

Mechanism of action

Inhibition of β-1,3-glucan synthesis disrupts fungal cell wall formation, leading to osmotic fragility and cell lysis in pathogenic fungi.

03

Biological functions

Fungal cell wall biosynthesisSynthesis of β-1,3-D-glucan polysaccharideMaintenance of cell wall integrityCell growth and morphogenesis in fungi
04

Disease associations

Infection (specifically, fungal infections, as it is not present in humans)Antifungal drug target
05

Safety considerations

Specificity: β-1,3-D-glucan is absent in humans, minimizing off-target effects, but resistance can emerge via FKS gene mutationsHypersensitivity and hepatic effects (adverse drug reactions to echinocandins)
06

Interacting drugs

Echinocandins (e.g., caspofungin, micafungin, anidulafungin)

1 more in the full profile.

07

Biomarkers

Serum β-D-glucan levels (used in diagnosis/monitoring of invasive fungal infections due to β-1,3-D-glucan cell wall release)

Beyond the preview

Go deeper on β-1,3-D-glucan synthase enzyme complex (Fks1 complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on β-1,3-D-glucan synthase enzyme complex (Fks1 complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call